Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Vertex Pharma (VRTX) Tops Q4 EPS by 26c; Guides FY Revenue
February 7, 2023 4:02 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.79, $0.26 better than the analyst estimate of $3.53. Revenue for the quarter came in at $2.3 billion versus the consensus estimate of $2.3 billion.
GUIDANCE:
Vertex Pharma sees Q1 2023 revenue of $9.55-9.7 billion, versus the consensus... More
